ResMed (NYSE:RMD) - Prezzo delle azioni, notizie e analisi

RMD Panoramica delle azioni

ResMed Inc. sviluppa, produce, distribuisce e commercializza dispositivi medici e applicazioni software basate su cloud per il mercato sanitario. Maggiori dettagli

RMD analisi fondamentale
Punteggio fiocco di neve
Valutazione	5/6
Crescita futura	2/6
Prestazioni passate	6/6
Salute finanziaria	6/6
Dividendi	4/6

Premi

Negoziato a 29.2% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 11.06% all'anno

Gli utili sono cresciuti del 22.8% nell'ultimo anno

Negoziato a un buon valore rispetto ai pari e al settore

Analisi del rischio

Non sono stati rilevati rischi per RMD dai nostri controlli di rischio.

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

WarrenAI

Based on Analyst Price Targets

Global Expansion And Innovative Tech Propel Market Leadership In Sleep Health Solutions

Key Takeaways Expanding the AirSense 11 platform and launching innovative CPAP products could boost revenue and market share significantly worldwide. Strategic investments in AI and digital health platforms are expected to improve patient outcomes, operational efficiencies, and long-term earnings growth.

View narrative

US$253.39

4.7% undervalued

7.67%

Revenue growth p.a.

Updated

ResMed Inc. Concorrenti

IDEXX Laboratories

NasdaqGS:IDXX

US$34.1b

DexCom

NasdaqGS:DXCM

US$29.2b

Edwards Lifesciences

NYSE:EW

US$41.4b

GE HealthCare Technologies

NasdaqGS:GEHC

US$37.7b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per ResMed
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$241.55
Massimo di 52 settimane	US$260.49
Minimo di 52 settimane	US$151.95
Beta	0.69
1Variazione di 1 mese	0.62%
Variazione a 3 mesi	8.12%
Variazione di 1 anno	58.28%
3Variazione a 3 anni	-5.27%
Variazione a 5 anni	60.15%
Variazione dall'IPO	35,851.63%

Notizie e aggiornamenti recenti

Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why

Nov 13

We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease

Nov 01

Recent updates

Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why

Nov 13

We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease

Nov 01

Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Oct 20

ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 47% Above Its Share Price

Oct 08

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued

Jul 02

ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Apr 30

Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Apr 30

ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

Apr 18

With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Mar 22

Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

Mar 10

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Feb 12

Why ResMed Is One Of My Top Picks In 2024

Jan 22

A First Look At ResMed

Jan 09

ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

Dec 20

Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital

Dec 06

Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Nov 10

Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?

Nov 01

ResMed: Weight-Loss Drug Worries Provide Buying Opportunity

Oct 28

ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity

Sep 12

ResMed Has Become A Steal (Rating Upgrade)

Aug 10

ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year

Aug 07

ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger

Jul 30

Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

Jul 16

Compound Your Wealth With ResMed

Jul 04

A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)

Jul 02

We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt

May 26

Rendimenti per gli azionisti

	RMD	US Medical Equipment	US Mercato
7D	2.6%	-0.4%	-1.0%
1Y	58.3%	20.3%	30.3%

Ritorno vs Industria: RMD ha superato il US Medical Equipment che ha restituito 20.3 % nell'ultimo anno.

Rendimento vs Mercato: RMD ha superato il mercato US che ha restituito 30.3 % nell'ultimo anno.

Volatilità dei prezzi

Is RMD's price volatile compared to industry and market?
RMD volatility
RMD Average Weekly Movement	4.2%
Medical Equipment Industry Average Movement	8.2%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: RMD non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 4% ) di RMD è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1989	9,980	Mick Farrell	www.resmed.com

ResMed Inc. sviluppa, produce, distribuisce e commercializza dispositivi medici e applicazioni software basate su cloud per i mercati della sanità. L'azienda opera in due segmenti, Sleep and Respiratory Care e Software as a Service. L'azienda offre diversi prodotti e soluzioni per una serie di disturbi respiratori, tra cui ApneaLink Air, un dispositivo diagnostico portatile che misura l'ossimetria, lo sforzo respiratorio, il polso, il flusso nasale e il russare; e NightOwl, un dispositivo diagnostico portatile, collegato al cloud e monouso che misura l'AHI sulla base del tono arterioso periferico derivato, dell'actigrafia e dell'ossimetria per diverse notti.

ResMed Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di ResMed con la sua capitalizzazione di mercato?
RMD statistiche fondamentali
Capitalizzazione di mercato	US$34.94b
Guadagni(TTM)	US$1.11b
Ricavi(TTM)	US$4.81b

31.9x

Rapporto P/E

7.4x

Rapporto P/S

RMD è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
RMD Conto economico (TTM)
Ricavi	US$4.81b
Costo del fatturato	US$2.00b
Profitto lordo	US$2.80b
Altre spese	US$1.69b
Guadagni	US$1.11b

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	7.58
Margine lordo	58.33%
Margine di profitto netto	23.15%
Rapporto debito/patrimonio netto	13.0%

Come si è comportato RMD nel lungo periodo?

Vedi performance storica e confronto

Dividendi

0.9%

Rendimento attuale del dividendo

26%

Rapporto di remunerazione

RMD paga dividendi affidabili?

Vedere la storia dei dividendi e i benchmark di RMD

Quando è necessario acquistare RMD per ricevere un dividendo imminente?
ResMed date dei dividendi
Data di stacco del dividendo	Nov 07 2024
Data di pagamento dei dividendi	Dec 12 2024
Giorni fino al dividendo Ex	15 days
Giorni prima della data di pagamento dei dividendi	20 days

RMD paga dividendi affidabili?

Vedere la storia dei dividendi e i benchmark di RMD

RMD Panoramica delle azioni

Premi

Analisi del rischio

Global Expansion And Innovative Tech Propel Market Leadership In Sleep Health Solutions

ResMed Inc. Concorrenti

NasdaqGS:IDXX

US$34.1b

NasdaqGS:DXCM

US$29.2b

NYSE:EW

US$41.4b

NasdaqGS:GEHC

US$37.7b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why

CEO & Chairman notifies of intention to sell stock

We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease

First quarter dividend of US$0.53 announced

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

ResMed Inc. Declares Quarterly Cash Dividend, Payable on December 12, 2024

Recent updates

Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why

CEO & Chairman notifies of intention to sell stock

We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease

First quarter dividend of US$0.53 announced

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

ResMed Inc. Declares Quarterly Cash Dividend, Payable on December 12, 2024

Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today

CEO & Chairman notifies of intention to sell stock

ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 47% Above Its Share Price

ResMed Inc., Annual General Meeting, Nov 20, 2024

ResMed Unveils New Collection of Digital and Personalized Solutions Designed to Improve Sleep Health

Why ResMed's Rally Is Just Getting Started

ResMed Inc.'s (NYSE:RMD) Earnings Haven't Escaped The Attention Of Investors

CEO & Chairman notifies of intention to sell stock

ResMed Elects Christopher DelOrefice to the Board

CEO & Chairman notifies of intention to sell stock

Chief Product Officer recently sold US$10m worth of stock

ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53

Fourth quarter dividend increased to US$0.53

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

ResMed Inc. Declares Quarterly Cash Dividend, Payable on September 19, 2024

Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?

Returns On Capital Are A Standout For ResMed (NYSE:RMD)

CEO & Chairman notifies of intention to sell stock

ResMed Inc. to Report Q4, 2024 Results on Aug 01, 2024

ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued

CEO & Chairman notifies of intention to sell stock

Now 22% undervalued

CEO & Chairman notifies of intention to sell stock

Investor sentiment improves as stock rises 19%

ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly

Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Third quarter dividend of US$0.48 announced

ResMed Inc. Declares Quarterly Cash Dividend, Payable on June 13, 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear

ResMed Inc. to Report Q3, 2024 Results on Apr 25, 2024

With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case

Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future

ResMed Inc. Announces the U.S. Launch of the AirFit F40

Founder recently sold US$5.0m worth of stock

Founder notifies of intention to sell stock

An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued

Price target increased by 7.3% to US$203

Upcoming dividend of US$0.48 per share at 1.0% yield

Second quarter dividend of US$0.48 announced

Second quarter 2024 earnings released: EPS: US$1.42 (vs US$1.53 in 2Q 2023)

ResMed Inc. Declares Quarterly Cash Dividend, Payable on March 14, 2024

Why ResMed Is One Of My Top Picks In 2024

A First Look At ResMed

ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk

ResMed Secures Significant Victory in Patent Fight Against New York University

Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital

Resmed Inc. Announces Board Changes

Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now

Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?

Upcoming dividend of US$0.48 per share at 1.4% yield